مؤتمر
Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-life experience from Belgium
| العنوان: | Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-life experience from Belgium |
|---|---|
| المؤلفون: | Moreno, C, Lasser, L, DELWAIDE, Jean, Starkel, P, Laleman, W, Langlet, P, Reynaert, H, Bourgeois, S, Negrin Dastis, S, Gustot, T, Francque, S, Geerts, A, Van Steenkiste, C, de Galocsy, C, Assene, C, Orlent, H, Nkuize, M, Degre, D |
| المصدر: | Hepatology, 62 (1), 746 (2015-10); The Liver Meeting, San Francisco, United States [US], du 13 novembre 2015 au 17 novembre 2015 |
| بيانات النشر: | Wiley, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Hepatitis C, Genotype 4, Simeprevir, Human health sciences, Gastroenterology & hepatology, Sciences de la santé humaine, Gastroentérologie & hépatologie |
| الوصف: | Background: All-oral, interferon-free regimens that combinedirect-acting antiviral drugs have significantly advanced thetreatment of hepatitis C (HCV), especially for genotype 1(G1)patients. However, efficacy and safety data of interferon-freeregimens in HCV genotype 4 (G4) patients are scarce. In Belgium,Sofosbuvir (SOF) and Simeprevir (SMV) treatment isavailable since January 2015 for G4 patients with advancedfibrosis (F3-F4 METAVIR) for 12 weeks. Methods: analysis ofHCV G4 patients receiving SOF and SMV treatment in Belgium.The aim of the study was to evaluate the safety and efficacyof the treatment. Results: 73 G4 patients were enrolled inthis data collection including 32 (43.8%) patients with severefibrosis F3 and 41(56.2%) cirrhotic patients. The study populationcomprised 58.9% male, 77.8% treatment experiencedpatients. Median age was 59 [51-66] years and 5 patientswere HCV/HIV co-infected. 24 patients received the treatmentassociated with ribavirin, 11/32 (34.37%) of patients withadvanced fibrosis and 13/41 (31.71%) of cirrhotic patients. Incirrhotic patients, median MELD and Child-Pugh score were 9[7-12.5] and 5 [5-6], 46.2% had platelet below 100.000/mmand 28.6% had albumin below 35 g/L. W4 HCV RNA wasundetectable in 31.25% (15/48). 9 of the 15 patients withundetectable W4 HCV RNA received RBV. At W12, 100%(23/23) had HCV RNA below the limit of quantification, with6/23 still detectable. All SVR12 data will be available at thetime of presentation. No patient experienced serious adverseevent. Conclusions: these preliminary results in difficult-to-treatG4 HCV patients show that SOF/SIM +/- RBV treatment is safeand seems promising, in line with that was observed in G1HCV patients. |
| نوع الوثيقة: | conference paper http://purl.org/coar/resource_type/c_5794 conferenceObject peer reviewed |
| اللغة: | English |
| Relation: | urn:issn:0270-9139; urn:issn:1527-3350 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/191663 |
| حقوق: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الأكسشن: | edsorb.191663 |
| قاعدة البيانات: | ORBi |
| الوصف غير متاح. |